Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Tracon Pharma (TCON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,051
  • Shares Outstanding, K 29,937
  • Annual Sales, $ 3,000 K
  • Annual Income, $ -34,960 K
  • 60-Month Beta 2.78
  • Price/Sales 7.56
  • Price/Cash Flow N/A
  • Price/Book 1.53
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.13
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.20
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +42.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.63 +22.22%
on 05/08/19
0.88 -12.50%
on 05/20/19
+0.09 (+13.04%)
since 04/22/19
3-Month
0.55 +40.00%
on 04/12/19
1.73 -55.49%
on 04/02/19
-0.26 (-25.24%)
since 02/22/19
52-Week
0.50 +54.00%
on 12/26/18
3.20 -75.94%
on 06/15/18
-1.76 (-69.50%)
since 05/22/18

Most Recent Stories

More News
Tracon: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Tracon Pharmaceuticals Inc. (TCON) on Tuesday reported a loss of $7.2 million in its first quarter.

TCON : 0.76 (-1.30%)
TRACON Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen...

SNPHF : 15.1500 (+2.02%)
TCON : 0.76 (-1.30%)
TRACON Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2019 / TRACON Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern...

TCON : 0.76 (-1.30%)
TRACON to Report First Quarter 2019 Company Highlights and Financial Results on May 14, 2019

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen...

SNPHF : 15.1500 (+2.02%)
TCON : 0.76 (-1.30%)
Investor Expectations to Drive Momentum within Workhorse Group, TRACON Pharmaceuticals, Capricor Therapeutics, Nuverra Environmental Solutions, Milestone Scientific, and Socket Mobile -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workhorse Group, Inc. (NASDAQ:WKHS),...

NESC : 0.0400 (-6.98%)
WKHS : 1.67 (-1.76%)
TCON : 0.76 (-1.30%)
MLSS : 0.34 (-2.86%)
NES : 5.23 (+2.55%)
CAPR : 0.35 (+2.94%)
SCKT : 2.35 (+1.73%)
TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen...

SNPHF : 15.1500 (+2.02%)
TCON : 0.76 (-1.30%)
TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen...

SNPHF : 15.1500 (+2.02%)
TCON : 0.76 (-1.30%)
Biotechs Search for Innovative Methods to Combat Common Diseases

Medical conditions are universally prevalent around the world, especially in areas where people lack access to proper healthcare. The most common forms of deadly medical conditions are coronary artery...

BTHCF : 0.1605 (+6.64%)
PTI : 1.09 (-4.39%)
AGN.CN : 0.215 (-2.27%)
PRTO : 0.45 (+9.76%)
KDMN : 2.23 (-0.45%)
TCON : 0.76 (-1.30%)
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen...

SNPHF : 15.1500 (+2.02%)
TCON : 0.76 (-1.30%)
TRACON Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 28, 2019 / TRACON Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 at...

TCON : 0.76 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade TCON with:

Business Summary

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company's product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California....

See More

Key Turning Points

2nd Resistance Point 0.87
1st Resistance Point 0.82
Last Price 0.76
1st Support Level 0.71
2nd Support Level 0.65

See More

52-Week High 3.20
Fibonacci 61.8% 2.17
Fibonacci 50% 1.85
Fibonacci 38.2% 1.53
Last Price 0.76
52-Week Low 0.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar